Candriam S.C.A. Karuna Therapeutics, Inc. Transaction History

Candriam S.C.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$161.01 - $317.85 $644,040 - $1.27 Million	-4,000 Reduced 6.54%	57,201 $18.1 Million
Q3 2023 Nov 13, 2023	SELL	$164.66 - $218.08 $987,960 - $1.31 Million	-6,000 Reduced 8.93%	61,201 $10.3 Million
Q1 2023 May 12, 2023	SELL	$161.33 - $204.36 $2.42 Million - $3.07 Million	-15,000 Reduced 18.25%	67,201 $12.2 Million
Q3 2022 Nov 10, 2022	SELL	$123.79 - $277.42 $807,853 - $1.81 Million	-6,526 Reduced 7.36%	82,201 $18.5 Million
Q2 2022 Aug 03, 2022	BUY	$93.97 - $143.33 $2.5 Million - $3.82 Million	26,632 Added 42.89%	88,727 $11.2 Million

Q1 2022 May 13, 2022	BUY	$98.9 - $132.37 $4.26 Million - $5.7 Million	43,039 Added 225.86%	62,095 $7.87 Million
Q4 2021 Feb 10, 2022	SELL	$110.64 - $159.4 $3.95 Million - $5.69 Million	-35,694 Reduced 65.19%	19,056 $2.5 Million
Q2 2021 Jul 20, 2021	BUY	$107.45 - $135.95 $5.88 Million - $7.44 Million	54,750 New	54,750 $6.24 Million

333K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.